Key PointsMedtronic had another solid quarter, with FCF expanding to support healthy dividend growth. The guidance is favorable and includes another year of steady, stable growth. Analysts Hold this stock and see it trading near the low end of the expected range with a possible 15% upside. 5 stocks we like better than MedtronicShares of Medtronic NYSE: MDT are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet an ...

Q4's results exhibited consistent organic revenue growth but it got hit by currency fluctuations and strategic divestitures.Medical technology specialist Medtronic (MDT -5.11%) released fourth-quarter and full-year data for fiscal 2024 on Thursday, May 23, that painted a nuanced financial picture.The company reported $8.59 billion in Q4 revenue which was up less than 1% year over year, yet it rose a robust 5.4% growth on an organic basis (growth not attributable to mergers and acquisitions). Medtronic's bus ...

文章核心观点 - 美敦力公司在2024财年第四季度的调整后每股收益为1.46美元,同比下降7.5%,但超出了分析师预期[1] - 2024财年全年调整后每股收益为5.53美元,同比增长4.5%,也超出了分析师预期[3] - 公司在各个业务板块都实现了中单位数以上的有机收入增长[6] 业务板块总结 心血管业务 - 心脏节奏与心力衰竭业务收入同比增长1.3%[8] - 结构性心脏与主动脉业务收入同比下降20.1%[8] - 冠脉与外周血管业务收入同比增长4.6%[8] 医疗外科业务 - 整体收入同比增长3.5%,其中手术与内窥镜业务增长4.1%,急诊护理与监护业务增长1.2%[9] 神经科学业务 - 整体收入同比增长5.6%,其中脑刺激治疗、神经调节和专科治疗业务均实现中单位数增长[10] 糖尿病业务 - 整体收入同比增长10.9%,其中美国市场实现两位数增长,得益于MiniMed 780G系统的持续推出[11] - 非美国发达市场实现高单位数增长,受益于MiniMed 780G系统的持续采用和CGM使用率的提高[11] 财务指标 - 毛利率同比下降56个基点至64.6%[12] - 研发费用同比增长5.5%至6.75亿美元,销售及管理费用同比增长5.7%至27.7亿美元[13] - 调整后营业利润率同比下降251个基点至24.5%[14] 其他 - 公司宣布将从2025财年第一季度开始将季度现金股利提高至0.70美元,年度股利为2.80美元[14] - 公司预计2025财年有机收入增长4-5%,全年调整后每股收益将在5.40-5.50美元之间[17][18]

A 27x earnings valuation and single-digit growth rate means Medtronic stock is probably going down.Medtronic (MDT -3.43%) stock slipped 2.8% through 10:15 a.m. ET this morning despite beating earnings forecasts in its fiscal Q4 2024 earnings report.Heading into earnings, analysts had the medical devices company pegged for a $1.45 per-share profit, but Medtronic "beat" by a penny, reporting $1.46 instead. Similarly, Medtronic exceeded expectations for $8.4 billion in sales by reporting $8.6 billion.And yet t ...

Medtronic (MDT) reported $8.59 billion in revenue for the quarter ended April 2024, representing a year-over-year increase of 0.5%. EPS of $1.46 for the same period compares to $1.57 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $8.44 billion, representing a surprise of +1.80%. The company delivered an EPS surprise of +0.69%, with the consensus EPS estimate being $1.45.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...

Medtronic (MDT) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.57 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.69%. A quarter ago, it was expected that this medical device company would post earnings of $1.26 per share when it actually produced earnings of $1.30, delivering a surprise of 3.17%.Over the last four quarters, the co ...

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cycles across many high-growth markets DUBLIN – May 23 ...

Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cycles across many high-growth marketsDUBLIN, May 23, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter (Q4) and fiscal year 2024 (FY24), which ended April 26, 2024.Key HighlightsQ4 revenue of $8.6 billion increased 0.5% as reported and 5.4% organicQ4 GAAP diluted ...

Medtronic plc’s (MDT) most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of the 2024 World Changing Ideas Awards. This marks the fourth consecutive year the company has been featured on the list, with previous honors received for GI Genius, the Micra leadless pacemaker and Medtronic LABS.Fast Company's annual World Changing Ideas list celebrates organizations that pursue innovation f ...

This photo taken on Nov. 8, 2023 shows a booth of Medtronic at the 6th China International Import ... [+] Expo CIIE in east China's Shanghai. (Photo by Wang Xiang/Xinhua via Getty Images)Xinhua News Agency via Getty ImagesMedtronic (NYSE: MDT) is scheduled to report its fiscal 2024 fourth-quarter results on Thursday, May 23 (fiscal ends in April). We expect Medtronic Medtronic stock to trade sideways post-Q4 results announcement, with its revenues and earnings expected to meet the street estimates. The comp ...